US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Xtrackers Nifty 500 India ETF

21.50

-0.0042-0.02%

Post-market: 21.500.0042+0.02%16:10 EDT

Volume:55

Turnover:1K

Market Cap:4.30M

PE:- -

High:21.50

Open:21.49

Low:21.50

Close:21.50

52wk High:27.40

52wk Low:20.52

Shares:200.00K

Float Shares:200.00K

Volume Ratio:0.06

T/O Rate:0.03%

Dividend:0.08

Dividend Rate:0.37%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Celltrion Submits Dual-Part EMA Application for Subcutaneous Rheumatoid Arthritis Drug

MT Newswires Live

Celltrion Submits South Korean IND for Subcutaneous Rheumatoid Arthritis Drug

MT Newswires Live

Indian Rupee Strengthens as Central Bank Intervenes in Onshore and Offshore Forex Markets

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

Industrial Minerals calls crucial shareholder vote on Galleon Metals acquisition

Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program

Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers

Is HBM Holdings (SEHK:2142) Fully Valued After Its Asthma IND Approval?

Simply Wall St.

Central Bank of India Sells US Dollars in Forex Market to Bolster Rupee, According to Traders

South African Fund Manager with $47 Billion AUM Reduces AI Chip Holdings, Boosts Exposure to Indian Equities

OXB Selected as GMP Manufacturing Partner to Support Manufacturing of Plowshare Therapies’ AAV Gene Therapy Programme

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models

HBM Holdings Wins NMPA IND Nod for Long-Acting Asthma Antibody HBM7575

ABBISKO-B Surges Over 5% on FDA Clearance for Investigational Drug Application of Oral Pan-KRAS Inhibitor

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Atrium Therapeutics announces FDA clearance of ATR 1072 IND application

HAIXI PHARMA's HXP089 Project Receives NMPA Approval for Glioblastoma Clinical Trial Application

Haisco Pharmaceutical's China IND Application for Novel Inflammatory Drug Accepted

MT Newswires Live

Neurotech Secures FDA IND Clearance for NTI164, Bolstering Global ASD Strategy

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/IND/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IND","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","market":"US","secType":"STK","nameCN":"Xtrackers Nifty 500 India ETF","latestPrice":21.5,"timestamp":1790971200000,"preClose":21.5042,"halted":0,"volume":55,"hourTrading":{"tag":"盘后","latestPrice":21.5042,"preClose":21.5,"latestTime":"16:10 EDT","volume":8,"amount":172,"timestamp":1790971804806,"change":0.0042,"changeRate":0.000195,"amplitude":0},"delay":0,"changeRate":-0.00019531068349442759,"floatShares":200001,"shares":200001,"eps":0,"marketStatus":"Market Closed","change":-0.0042,"latestTime":"10-02 16:00:00 EDT","open":21.49,"high":21.5,"low":21.5,"amount":1205,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":21.5042,"sharesOutstanding":200001,"nav":21.258,"aum":4251521.99,"dividendRate":0.003674,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":21.5042,"preClose":21.5,"latestTime":"16:10 EDT","volume":8,"amount":172,"timestamp":1790971804806,"change":0.0042,"changeRate":0.000195,"amplitude":0},"volumeRatio":0.06475158097165776},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","floatShares":200001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.06475158097165776,"shares":200001,"dividePrice":0.079,"high":21.5,"amplitude":0,"preClose":21.5042,"low":21.5,"week52Low":20.515,"pbRate":"--","week52High":27.4,"institutionHeld":0,"latestPrice":21.5,"eps":0,"divideRate":0.003674,"volume":55,"delay":0,"ttmEps":0,"open":21.49,"prevYearClose":24.78,"prevWeekClose":22.3,"prevMonthClose":21.62,"prevQuarterClose":21.62,"fiveDayClose":22.3,"twentyDayClose":23.195,"sixtyDayClose":22.865},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND\",params:#limit:5,,,undefined,":[{"date":"2026-06-18","symbol":"IND","amount":0.07775,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-18","defaultRemindTime":1781789400000,"name":"Xtrackers Nifty 500 India ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-18","currency":"USD","dateTimestamp":1781755200000,"payDate":"2026-06-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND\",market:\"US\",,,undefined,":[{"executeDate":"2026-06-18","recordDate":"2026-06-18","paymentDate":"2026-06-26","value":0.07775,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IND\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2653088115","title":"Celltrion Submits Dual-Part EMA Application for Subcutaneous Rheumatoid Arthritis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2653088115","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653088115?lang=en_us&edition=fundamental","pubTime":"2026-07-24 17:23","pubTimestamp":1784885030,"startTime":"0","endTime":"0","summary":"Celltrion  has submitted applications for its subcutaneous rheumatoid arthritis drug CT-P13 SC  to both the U.S. FDA  and the European Medicines Agency .The company seeks to demonstrate superiority over placebo at 12 weeks in a 296-patient, 52-week global Phase 3 trial, according to a bourse filing on Friday.The subcutaneous formulation, already approved for ulcerative colitis and Crohn's disease in multiple regions, aims to expand its indications and improve patient convenience through a broader treatment population.The company cautions that historically only about 10% of clinical trial drugs ultimately receive marketing approval, and results may fall short of expectations.While both filings share the same clinical design and commercial rationale, the EMA submission explicitly addresses the EU's revised Clinical Trials Regulation requiring separate Part 1  and Part 2  approvals.Both submissions support commercial differentiation through patient diversity, though investors are urged to","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IND","IND.AU","EMA","BK4081","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653700516","title":"Celltrion Submits South Korean IND for Subcutaneous Rheumatoid Arthritis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2653700516","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653700516?lang=en_us&edition=fundamental","pubTime":"2026-07-24 16:49","pubTimestamp":1784882944,"startTime":"0","endTime":"0","summary":"Celltrion  has filed a Phase 3 IND application with the MFDS for CT-P13 SC  in rheumatoid arthritis, aiming to demonstrate superiority over placebo at 12 weeks.The 296-patient, 52-week trial seeks to expand the drug's approved uses beyond ulcerative colitis and Crohn's disease, leveraging its subcutaneous formulation for patient convenience, according to a bourse filing on Friday.The company cautions that only about 10% of trial drugs ultimately gain marketing approval, and outcomes may not meet expectations.This filing, confirmed on Friday, also supports commercial differentiation and regulatory trends favoring patient diversity, though investors should review all risk disclosures.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182433727","title":"Indian Rupee Strengthens as Central Bank Intervenes in Onshore and Offshore Forex Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=1182433727","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182433727?lang=en_us&edition=fundamental","pubTime":"2026-07-24 12:20","pubTimestamp":1784866849,"startTime":"0","endTime":"0","summary":"Traders, who requested anonymity as they were not authorized to speak publicly, reported that the Reserve Bank of India (RBI) sold US dollars in both the offshore and onshore foreign exchange markets...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDIA","BK4585","BK4523","PIN","TAJX","BK4588","INDL","SMIN","FLIN","INQQ","FLIBF","INDE","IUmain","XCEM","IOPP","IND","SCIN","INCO","INDY","GLIN","ASGM","IMVP","INDA","EPI","GIND","NFTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653773779","title":"Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2653773779","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653773779?lang=en_us&edition=fundamental","pubTime":"2026-07-24 04:05","pubTimestamp":1784837100,"startTime":"0","endTime":"0","summary":"-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program for PM577a -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/23/3332566/0/en/Prime-Medicine-Announces-U-S-FDA-Clearance-of-Investigational-New-Drug-Application-for-PM577a-in-H1069Q-mutated-Wilson-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ICOP","COPP","IND","COPJ","CPXR","BK4535","CTA","WD","LABU","BK4588","BK4195","XME","UYM","BK4229","CPER","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653747032","title":"YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2653747032","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653747032?lang=en_us&edition=fundamental","pubTime":"2026-07-23 20:00","pubTimestamp":1784808000,"startTime":"0","endTime":"0","summary":"Taipei, Taiwan, July  23, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and op","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/23/3332099/0/en/YD-Bio-and-EG-BioMed-Conclude-Successful-Exhibition-at-BIO-Asia-Taiwan-2026-Highlighting-Innovations-in-Ophthalmology-Oncology-Diagnostics-and-Clinical-Services.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNGR","EG","BK4588","LU1169590202.USD","LU0211331839.USD","IE00B19Z3B42.SGD","LU1169589451.USD","BIO","IE0002270589.USD","IE00B19Z3581.USD","LU0077335932.USD","BK4585","BK4019","BK4121","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653667719","title":"Industrial Minerals calls crucial shareholder vote on Galleon Metals acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2653667719","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653667719?lang=en_us&edition=fundamental","pubTime":"2026-07-23 13:52","pubTimestamp":1784785964,"startTime":"0","endTime":"0","summary":"Industrial Minerals Limited ( ($AU:IND) ) has provided an update. Industrial Minerals Ltd has called a general meeting for 21 August 2026 in Pepper...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-calls-crucial-shareholder-vote-on-galleon-metals-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-calls-crucial-shareholder-vote-on-galleon-metals-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRGR","MTX","RSBA","IND","PICK","BK4535","BK4109"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653270035","title":"Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2653270035","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653270035?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:55","pubTimestamp":1784638500,"startTime":"0","endTime":"0","summary":"Silo continues to add technology assets as it expands its AI business and further develops its lead PTSD therapeutic candidate  AI agent platform prepares for commercial launch while SPC-15 regulatory","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/21/3330474/0/en/Silo-Pharma-Advances-Growth-Platforms-for-AI-Agent-Commercialization-and-Lead-PTSD-Drug-Program.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DBB","VTHR","BK4135","QTOC","AIPO","IND","ARTY","CHAT","AGIX","CNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653277003","title":"Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers","url":"https://stock-news.laohu8.com/highlight/detail?id=2653277003","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653277003?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:00","pubTimestamp":1784635200,"startTime":"0","endTime":"0","summary":"Company receives positive pre-IND feedback from US FDA for CLD-401, indicating agreement on its current development strategy as it advances towards a first-in-human study; targeting dosing first patie","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/21/3330378/0/en/Calidi-Biotherapeutics-Provides-Mid-Year-Corporate-Update-and-Future-Key-Value-Drivers.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023057109.AUD","IND","SG9999011746.SGD","BK4552","LU0269904917.USD","LU0359202008.SGD","BK4526","IE00BYTNYN87.SGD","BK4571","LU0359201612.USD","LU0509642566.USD","TME","BK4565","BK4080","IE00B12V2V27.USD","IE00BYQNZ168.SGD","SITC","BK4231","01698","LU0456842615.SGD","BK4509","BK4531","BK4563","BMS","BK4548","LU0828238088.HKD","LU2039709279.SGD","BK4108","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653627641","title":"Is HBM Holdings (SEHK:2142) Fully Valued After Its Asthma IND Approval?","url":"https://stock-news.laohu8.com/highlight/detail?id=2653627641","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653627641?lang=en_us&edition=fundamental","pubTime":"2026-07-21 18:16","pubTimestamp":1784629000,"startTime":"0","endTime":"0","summary":"HBM Holdings (SEHK:2142) is in focus after China’s National Medical Products Administration approved the Investigational New Drug application for HBM7575/SKB575, a long-acting bispecific antibody candidate for asthma co-developed with Kelun-Biotech.\nSee our latest analysis for HBM Holdings.\nThe IND approval appears to have reinforced interest in HBM Holdings, with the HK$11.96 share price supported by a 9.72% 1 month share price return and a very large 3 year total shareholder return, even...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/is-hbm-holdings-sehk2142-fully-valued-after-its-asthma-ind-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/is-hbm-holdings-sehk2142-fully-valued-after-its-asthma-ind-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HBM","MUYY","MUZ","COPP","DRMY","MIC","DISK","IND","HBMX","BK4588","RAM","BK1583","BK4168","MUD","DRAL","MUU","DCF","MULL","DRAM","02142","DRMP","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127672518","title":"Central Bank of India Sells US Dollars in Forex Market to Bolster Rupee, According to Traders","url":"https://stock-news.laohu8.com/highlight/detail?id=1127672518","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127672518?lang=en_us&edition=fundamental","pubTime":"2026-07-20 12:00","pubTimestamp":1784520022,"startTime":"0","endTime":"0","summary":"According to traders with knowledge of the matter, the Reserve Bank of India has been selling US dollars in both offshore and onshore foreign exchange markets to support the rupee. These traders...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOPP","INDE","FLIN","INDA","NDIA","EPI","BK4523","INDY","BK4588","FLIBF","NFTY","SCIN","INQQ","PIN","UDN","IND","UUP","INCO","BK4585","IMVP","SMIN","INDL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117398250","title":"South African Fund Manager with $47 Billion AUM Reduces AI Chip Holdings, Boosts Exposure to Indian Equities","url":"https://stock-news.laohu8.com/highlight/detail?id=1117398250","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117398250?lang=en_us&edition=fundamental","pubTime":"2026-07-17 16:52","pubTimestamp":1784278327,"startTime":"0","endTime":"0","summary":"A South African asset manager overseeing $47 billion has trimmed its investments in semiconductor manufacturers and increased its allocation to the Indian market, as market expectations for...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVGX","AVS","FLIN","INDH","BKF","PIN","BBEM","NFTY","QLVE","SEEM","AIBU","EEMV","AVEM","INDL","XCEM","INDE","AVGG","FLIBF","DFAE","AVGW","INQQ","INDY","BK4550","BK4585","IMVP","RWEM","EET","SMIN","WISE","XXCH","EQLT","BK4588","ASIA","XC","SCIN","LRNZ","VEU","MFEM","MEM","AVL","XSOE","MEMX","STXE","AVGU","BKEM","EEMA","FAI","IOPP","AIVC","ALAI","BK4523","EMXC","EPI","AIS","DEXC","HEEM","IND","KEMX","QEMM","BCHI","FEMR","GLIN","NDIA","PEMX","INCO","AIFD","SPEM","INDA","SCHE","XCNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651464104","title":"OXB Selected as GMP Manufacturing Partner to Support Manufacturing of Plowshare Therapies’ AAV Gene Therapy Programme","url":"https://stock-news.laohu8.com/highlight/detail?id=2651464104","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651464104?lang=en_us&edition=fundamental","pubTime":"2026-07-16 19:00","pubTimestamp":1784199600,"startTime":"0","endTime":"0","summary":"New client programme to be supported from OXB’s FDA-approved, commercial scale viral vector manufacturing facility in Durham, North Carolina, underscoring increasing global demand for OXB’s end-to-end","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/16/3328316/0/en/OXB-Selected-as-GMP-Manufacturing-Partner-to-Support-Manufacturing-of-Plowshare-Therapies-AAV-Gene-Therapy-Programme.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BK4139","JDOC","SYNB","BK4585","IBB","BK4588","CDMO","EES"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651246501","title":"Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2651246501","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651246501?lang=en_us&edition=fundamental","pubTime":"2026-07-15 21:05","pubTimestamp":1784120700,"startTime":"0","endTime":"0","summary":"Data show clade IIb from 2022 outbreak is 100 to 100,000-fold less virulent than clade IIa from 2003 outbreak  Three new models for investigating mpox infection and pathogenesis identified Tonix is ad","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/15/3327818/28908/en/Tonix-Pharmaceuticals-Announces-Publication-in-the-Peer-Reviewed-Journal-of-Virology-Assessing-Virulence-of-the-2022-Outbreak-Strain-of-Mpox-in-New-Animal-Models.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","CNS","BK4139","BK4135","RDC","IND","ASM","BK4188","TNXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651454611","title":"HBM Holdings Wins NMPA IND Nod for Long-Acting Asthma Antibody HBM7575","url":"https://stock-news.laohu8.com/highlight/detail?id=2651454611","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651454611?lang=en_us&edition=fundamental","pubTime":"2026-07-15 18:07","pubTimestamp":1784110075,"startTime":"0","endTime":"0","summary":"HBM Holdings Ltd. ( ($HK:2142) ) just unveiled an announcement. HBM Holdings Ltd. reported that China’s National Medical Products Administration ha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/hbm-holdings-wins-nmpa-ind-nod-for-long-acting-asthma-antibody-hbm7575?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/hbm-holdings-wins-nmpa-ind-nod-for-long-acting-asthma-antibody-hbm7575?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAM","BK4588","DRAM","COPP","DRAL","BK4168","HBM","MULL","MUD","IND","MUU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140504842","title":"ABBISKO-B Surges Over 5% on FDA Clearance for Investigational Drug Application of Oral Pan-KRAS Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=1140504842","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140504842?lang=en_us&edition=fundamental","pubTime":"2026-07-15 11:26","pubTimestamp":1784085985,"startTime":"0","endTime":"0","summary":"Shares of ABBISKO-B (HKEX: 02256) have risen by more than 5%. At the time of writing, the stock is up 5.53% to HKD 11.25, with a turnover of HKD 2.5452 million.The move follows a recent company...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2476274308.USD","LABU","BK1574","LU2778985437.USD","VXUS","09939","159938","BK4585","BK1161","IND","LU2476274720.SGD","IE00B5MMRT66.SGD","KCAI","02256","IE00BPRC5H50.USD","LU2488822045.USD","IE00B543WZ88.USD","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651738105","title":"Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2651738105","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651738105?lang=en_us&edition=fundamental","pubTime":"2026-07-14 20:00","pubTimestamp":1784030400,"startTime":"0","endTime":"0","summary":"–Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs – –SNDX-62122, a next-generation menin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/14/3326768/0/en/Syndax-to-Highlight-Late-Stage-Programs-and-Unveil-New-Pipeline-Assets-at-R-D-Event.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651172282","title":"Atrium Therapeutics announces FDA clearance of ATR 1072 IND application","url":"https://stock-news.laohu8.com/highlight/detail?id=2651172282","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651172282?lang=en_us&edition=fundamental","pubTime":"2026-07-14 18:40","pubTimestamp":1784025625,"startTime":"0","endTime":"0","summary":"Atrium Therapeutics (RNA) announced that the FDA has cleared its investigational new drug, or IND, application allowing the company to move forward...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atrium-therapeutics-announces-fda-clearance-of-atr-1072-ind-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atrium-therapeutics-announces-fda-clearance-of-atr-1072-ind-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","RNA","BK4126","BK4139","BK4585","IE0009354923.USD","ATR","BK4588","IND","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116749786","title":"HAIXI PHARMA's HXP089 Project Receives NMPA Approval for Glioblastoma Clinical Trial Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1116749786","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116749786?lang=en_us&edition=fundamental","pubTime":"2026-07-14 17:13","pubTimestamp":1784020411,"startTime":"0","endTime":"0","summary":"The company's self-developed HXP089 project, intended for the treatment of glioblastoma (GBM), has received approval for its Investigational New Drug (IND) application from the Center for Drug...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","02637","IBBQ","BK1191","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651127121","title":"Haisco Pharmaceutical's China IND Application for Novel Inflammatory Drug Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=2651127121","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651127121?lang=en_us&edition=fundamental","pubTime":"2026-07-14 13:09","pubTimestamp":1784005753,"startTime":"0","endTime":"0","summary":"Haisco Pharmaceutical  said China's medical products regulator has accepted the investigational new drug application for HSK60002 tablets.The drug was independently developed for treating inflammatory diseases, according to a Tuesday filing with the Shenzhen bourse.Shares of the company fell 1% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IND","BK0028","BK0188","002653","BK0239","BK0033","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651147194","title":"Neurotech Secures FDA IND Clearance for NTI164, Bolstering Global ASD Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2651147194","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651147194?lang=en_us&edition=fundamental","pubTime":"2026-07-14 07:21","pubTimestamp":1783984875,"startTime":"0","endTime":"0","summary":"Neurotech International ( ($AU:NTI) ) has provided an update. Neurotech International has secured U.S. FDA clearance for its Investigational New Dr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurotech-secures-fda-ind-clearance-for-nti164-bolstering-global-asd-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurotech-secures-fda-ind-clearance-for-nti164-bolstering-global-asd-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IND","ASD","BK4585","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}